Inventor · disambiguated record
Henry Hongjun Ji
Also filed as: JI HENRY · JI HENRY H · JI HENRY HONGJUN
7 granted patents·26 pending applications·21 citations·filing 2002–2024
79Inventor score
Files withSORRENTO THERAPEUTICS INC18HUMAN GENOME SCIENCES INC2STRATAGENE CALIFORNIA2VIVASOR INC2CELULARITY INC1
Top patents by PatentIndex Score
33 records- 0184US7109178B2Method for ligating nucleic acids and molecular cloningSTRATAGENE CALIFORNIA·Filed 2002·Granted Sep 19, 2006·13 cites·6 claims
- 0273US12029725B2Method for treating osteoarthritis pain by administering resiniferatoxinVIVASOR INC·Filed 2020·Granted Jul 9, 2024·1 cites·18 claims
- 0373US7335489B2Polynucleotides encoding a protein kinase C inhibitor protein and methods of using these polynucleotidesHUMAN GENOME SCIENCES INC·Filed 2003·Granted Feb 26, 2008·1 cites·17 claims
- 0471US7405062B2Method for cloning variable domain sequences of immunological gene repertoireSAN DIEGO ANTIBODY·Filed 2002·Granted Jul 29, 2008·6 cites·18 claims
- 0566US2009197278A9Antibodies to hADA2HUMAN GENOME SCIENCES INC·Filed 2008·Application pending·0 cites
- 0664US2025161261A1Method for Treating Osteoarthritis Pain by Administering ResiniferatoxinVIVASOR INC·Filed 2024·Application pending·0 cites
- 0763US10925968B2Cell internalizing compoundsSORRENTO THERAPEUTICS INC·Filed 2019·Granted Feb 23, 2021·0 cites·17 claims
- 0859US12201608B2Methods for treating Parkinson's disease by administering resiniferatoxinSORRENTO THERAPEUTICS INC·Filed 2021·Granted Jan 21, 2025·0 cites·11 claims
- 0959US2021138075A1Cell internalizing compoundsSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1057US2024197881A1Dimeric Antigen Receptors (DARs) that Bind GD2SORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1155US2025000841A1Administration of Resiniferatoxin For Treatment of Prostate CancerSORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1255US2023061838A1Dimeric Antigen Receptors (DAR) That Bind CD20SORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1355US2023406907A1Neutralizing Antibodies that Bind the SARS-COV-2 S ProteinSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1455US2023416343A1Neutralizing Antibodies that Bind the SARS-COV-2 S ProteinSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1554US2024019426A1Lateral Flow Devices for High Sensitivity Detection of Coronavirus Infection, and Methods of Making and Using the SameSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1653US2024090908A1Device for microliter-scale lymphatic delivery of coronavirus vaccines and methods of use thereofSORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1753US2022251168A1Dimeric Antigen Receptors (DAR) that Bind BCMASORRENTO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1853US2007072297A1Method for ligating nucleic acids and molecular cloningSTRATAGENE CALIFORNIA·Filed 2006·Application pending·0 cites
- 1953US2009042740A1Novel Method for Cloning Variable Domain Sequences of Immunological Gene RepertoireJI HENRY·Filed 2008·Application pending·0 cites
- 2052US2023168245A1Lateral Flow Device for Detection of Neutralizing Antibodies Against SARS-COV-2SORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2151US2025092363A1Placenta-derived allogeneic car-t cells and uses thereofCELULARITY INC·Filed 2020·Application pending·0 cites
- 2251US2023071405A1Natural Killer Cells for Treatment of Coronavirus InfectionSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2350US2022183999A1Cannabidiol Pharmaceutical CompositionsSORRENTO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2450US2023143545A1Treating Pulmonary Inflammatory Disease Associated With Covid-19 By Administering ResiniferatoxinSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2550US2023270713A1Administration of Resiniferatoxin For Treatment of Bladder Pain or Bladder CancerSORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2648US12180294B2Dimeric antigen receptorsSORRENTO THERAPEUTICS INC·Filed 2020·Granted Dec 31, 2024·0 cites·10 claims
- 2747US2004214222A1Gene targeting methods and vectorsGENOME BIOSCIENCES LLC·Filed 2004·Application pending·0 cites
- 2845US2004087526A1Therapeutically useful compositions of DNA-RNA hybrid duplex constructsFiled 2003·Application pending·0 cites
- 2945US2023167191A1Memory Dimeric Antigen Receptors (mDARs)SORRENTO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3044US2003135872A1Gene targeting methods and vectorsFiled 2002·Application pending·0 cites
- 3144US2003022218A1Gene targeting methods and vectorsFiled 2002·Application pending·0 cites
- 3237US2013224203A1Pharmaceutical Composition of Recombinant Polyclonal ImmunoglobulinsLEE TIEN-LI·Filed 2012·Application pending·0 cites
- 3336US2011250642A1Method for Displaying AntibodiesSorrento Therapeutics·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Henry Hongjun Ji files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →